The landscape for large pharmaceutical companies has changed radically in the last year.

Their model used to be that they would spend huge sums on R&D and then push blockbuster drugs into the market.

These drugs would often be worth billions of dollars in revenue each year, and were protected from competition by patents.

But, a number of those patents are expiring, and generic manufacturers are moving into the drug market with cheaper versions of the products.

The success of this trend is fueled by government desires to keep down health care costs.

Early this year, Pfizer (NYSE: PFE) cut 10,000 jobs. The company said that rising competition from generics would pressure its operating profits for the next several years.

Wall Street analysts pegged the drop in Pfizer's annual revenue due to generic competition at as much as $14 billion a year. The biggest drug in Pfizer's stable about to go "off patent" is its hugely successful cholesterol drug Lipitor.

URCH Publishing recently put out a report that forecast $100 billion in sales of big pharma drugs will be at risk between 2007 and 2011. Bristol-Myers Squibb (NYSE: BMY), Takeda, AstraZeneca and Eli Lilly (NYSE: LLY) have 40% of their revenue competing with new generics and for Merck (NYSE: MRK) and Pfizer the figure is closer to 50%.

It will be a windfall for generic companies, which may be able to add $20 billion in revenue over the next five years.

Investors have known for some time that this day would come. The patent expiration dates for key drugs are readily available. And, the growing concern shows in the stock prices. Over the last five year, shares in Pfizer are down 40%. Shares in Bristol-Myers are down 46% and shares in Merck are off 28%.

Perhaps the best example of how investors have been able to benefit from the trend toward generics is the public company Teva Pharmaceutical (Nasdaq: TEVA).

Shares in the Israeli company are up over 150% during the last five years. One of its rivals, Barr Pharmaceuticals (NYSE: BRL), has seen its stock up 50% over that same period.

The pressure on drug prices is mounting as both the state and federal governments try to hold down medical costs. Eleven governors recently banded together in an attempt to drive down the cost of insulin.

Consumers, the government, and private insurers spend $3.3 billion on the diabetes drug each year. Analysts say that a generic version could push those costs down by 25%.

The remaining question for big pharma shareholders is whether the large R&D operations at these companies can create patented drugs to replace those that are now the target of the generics companies.

With falling revenue opportunities the money for R&D may not be so plentiful, and that is a very big problem.

Looking to cook up a market-stomping stock portfolio? Check out our FREE report "7 Ingredients to Market Beating Stocks" and get started right now!

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center